It has been demonstrated that CTLA4 and PD-1, along with its ligand PD-L1, have demonstrated significant therapeutic efficacy in cancers, including non-small cell lung cancer, metastatic melanoma, and bladder cancer [47]. Here, CTLA4 is linked to non-small cell lung carcinoma.